Greenfield Savings Bank Has $643,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Greenfield Savings Bank lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 28.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 612 shares of the biopharmaceutical company’s stock after purchasing an additional 136 shares during the period. Greenfield Savings Bank’s holdings in Regeneron Pharmaceuticals were worth $643,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after purchasing an additional 91,956 shares during the last quarter. Capital International Investors grew its stake in Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after buying an additional 213,038 shares during the last quarter. Putnam Investments LLC grew its stake in Regeneron Pharmaceuticals by 2.1% in the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after buying an additional 24,329 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Regeneron Pharmaceuticals by 25.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after buying an additional 184,561 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in Regeneron Pharmaceuticals by 12.4% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock valued at $567,864,000 after buying an additional 59,769 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Down 1.7 %

Shares of NASDAQ REGN opened at $996.05 on Tuesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20. The firm has a 50 day moving average price of $1,125.65 and a two-hundred day moving average price of $1,037.99. The stock has a market cap of $109.80 billion, a P/E ratio of 29.43, a price-to-earnings-growth ratio of 3.55 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same period in the prior year, the company posted $8.79 EPS. The company’s revenue was up 12.3% on a year-over-year basis. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on REGN. Piper Sandler upped their price target on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. Truist Financial reiterated a “buy” rating and issued a $1,200.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Leerink Partners reiterated a “market perform” rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. JPMorgan Chase & Co. boosted their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Finally, Royal Bank of Canada boosted their price objective on shares of Regeneron Pharmaceuticals from $1,252.00 to $1,260.00 and gave the company an “outperform” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,119.00.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 8,033 shares of company stock worth $9,399,345 over the last three months. 7.48% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.